

9 May 2023

Physiomics plc
("Physiomics" or "the Company")

Publication of article in Frontiers in Oncology

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development and personalised medicine solutions, is pleased to announce the publication of an original article "Should personalised dosing have a role in cancer treatment?" in a special edition of the journal "Frontiers in Oncology" focused on the FDA's Project Optimus. The full article can be accessed via the following link:

[https://www.frontiersin.org/articles/10.3389/fonc.2023.1154493/full?
&utm_source=Email_to_authors &utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=](https://www.frontiersin.org/articles/10.3389/fonc.2023.1154493/full?utm_source=Email_to_authors&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=)

Project Optimus has relevance to Physiomics both in its core consulting business and its personalised oncology initiatives. In core consulting, Project Optimus encourages and some would say even mandates biotech and pharma companies to fully utilise all available non-clinical and clinical data to make informed decisions about clinical trial design and biologically effective dose. The Company believes that there is an increasing expectation that companies meeting with the FDA should have utilised mathematical modelling in support of clinical trial design and dosing decision making. The Company has first hand experience of this through the translational modelling work it has completed for multiple small and medium sized clients in recent years.

Looking beyond drug development, the Company sees a clear implication of Project Optimus on dosing of approved drugs in cancer. The vast majority of cancer drugs are still approved on a "one size fits all" basis with, at most, adjustments in dosing being made to account for body weight or surface area of individual patients. The Company believes that the future direction of cancer drug dosing will take into account its effect in each individual and we believe that our personalised dosing tool is a clear step towards achieving that goal.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO
+44 (0)1865 784 980

Hybridan LLP (Broker)

Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help

biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAUWUNROUUVRAR